This study profiles cystobactamids' off-target effects in eukaryotes, showing safety, superoxide reduction, and SCARB1 inhibition with therapeutic potential.

npj Drug Discovery. · Aug 6, 2025Peer-reviewedPharmacology & Toxicology

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

Chelsea E. Cunningham, Frederick S. Vizeacoumar, Yue Zhang, Liliia Kyrylenko, Simon Both, Vincent Maranda, He Dong, Jared D. W. Price, Peng Gao, Konrad Wagner, Yingwen Wu, Mary Lazell-Wright, Ashtalakshmi Ganapathysamy, Rithik Hari, Kalpana Kalyanasundaram Bhanumathy, , Franco J. Vizeacoumar

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

Cell Genomics · May 9, 2025Peer-reviewedCancer Biology

CRUP: A comprehensive framework to predict condition-specific regulatory units

Anna Ramisch, Verena Heinrich, Laura V. Glaser, Alisa Fuchs, Xinyi Yang, Philipp Benner, Robert Schöpflin, Na Li, Sarah Kinkley, Anja Römer-Hillmann, John Longinotto, Steffen Heyne, Beate Czepukojc, Sonja M. Kessler, Alexandra K. Kiemer, , Martin Vingron

CRUP predicts condition-specific regulatory units by analyzing histone modification ChIP-seq data and linking enhancers to target genes in rheumatoid arthritis.

Genome biology · Nov 7, 2019Peer-reviewedBioinformatics